InsidersTradesSigma
Track the CHARLES RIVER LABORATORIES INTERNATIONAL, INC. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, CHARLES RIVER LABORATORIES INTERNATIONAL, INC. has recorded 22 public disclosures. Market capitalisation: €14bn. The latest transaction was disclosed on 27 August 2026 (Levée d'options). Among the most active insiders: FOSTER JAMES C. The full history is free.
22
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€10m
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Buy (bullish), based on 14 analysts. Average price target: US$281.00.
36Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 24,235 of 29,064 companies
28.1
score / 100
Value31
Quality25
FCF yld3.7%
Earn yld-1.0%
EV/EBITDA40.4x
ROE-7.5%
Gross mgn33%
Net mgn-3.6%
Debt/EBITDA6.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 August 2026
Declarations22 total
21,132 shares@ US$194.120.029% mcap15.3% of flowCommon StockSEC:0001100682-26-000140:0
12,429 shares@ US$208.440.018% mcap9.7% of flowCommon StockSEC:0001100682-26-000140:1
33,561 shares@ US$300.000.071% mcap37.5% of flowCommon StockSEC:0001100682-26-000140:2
33,561 shares@ US$299.930.070% mcap100.0% of flowCommonSEC144:0001969223-26-000955
6,645 shares@ US$260.000.014% mcap100.0% of flowCommon StockSEC144:0001969223-26-000852
4,179 shares@ US$260.000.0086% mcap100.0% of flowCommonSEC144:0001969223-26-000853
5,046 shares@ US$263.000.011% mcap100.0% of flowCommon StockSEC:0001100682-26-000120:0
75,000 sharesCommon StockSEC:0001100682-26-000111:0
1,529 shares0Common StockSEC:0001100682-26-000105:1
3,386 shares0Common StockSEC:0001100682-26-000107:0
153,361 shares0Common StockSEC:0001100682-26-000109:0
153,361 shares0Common StockSEC:0001100682-26-000109:1
20,000 shares0Common StockSEC:0001100682-26-000109:2
20,000 shares0Common StockSEC:0001100682-26-000109:3
1,529 shares0Common StockSEC:0001100682-26-000105:0
3,386 shares0Common StockSEC:0001100682-26-000107:1
10,000 shares0Common StockSEC:0001100682-26-000109:4
10,000 shares0Common StockSEC:0001100682-26-000109:5
946 shares@ US$135.04100.0% of flowCommon StockSEC:0001127602-25-016733:0
946 shares@ US$135.04100.0% of flowCommon StockSEC:0001127602-25-016729:0
946 shares@ US$135.04100.0% of flowCommon StockSEC:0001127602-25-016726:0
481 shares@ US$135.04100.0% of flowCommon StockSEC:0001127602-25-016724:0
22 of 22 declarations
关于 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Charles River Laboratories International, Inc. (NYSE: CRL) 是一家在美国纽约证券交易所上市的美国公司，被广泛认为是制药、生物技术、政府和学术客户加速研究和药物开发的全球合作伙伴。公司总部位于马萨诸塞州威尔明顿，其运营历史可追溯到 1947 年，而目前的法人实体成立于 1994 年，并于 2000 年完成首次公开募股。随着时间的推移，Charles River 已建立起作为生命科学行业高度专业化的“镐和铲”供应商的声誉，提供任务关键型研究工具和外包服务，而非市场化的治疗方法。([sec.gov](https://www.sec.gov/Archives/edgar/data/1100682/000110068224000007/crl-20231230.htm?utm_source=openai)) 公司的业务围绕三个核心部门组织：研究模型和服务 (RMS)、发现和安全评估 (DSA) 以及制造解决方案。RMS 提供研究模型、实验动物和相关服务。DSA 涵盖药物发现支持、药理学、毒理学、病理学和面向监管的测试服务，帮助候选药物通过临床前开发。制造解决方案通过与制造相关的能力和先进疗法开发（包括细胞和基因疗法相关服务）为客户提供支持。这种组合使 Charles River 在药物开发价值链中拥有广泛的业务，并与大型制药公司和小型生物技术创新者建立了多个接触点。([ir.criver.com](https://ir.criver.com/?utm_source=openai)) 从竞争角度来看，Charles River 凭借其科学深度、全球足迹和综合产品脱颖而出。它在临床前研究和安全评估领域占据强势地位，这些领域严格的监管和专业技术构成了重要的进入壁垒。公司还强调数字化和人工智能驱动的能力，包括数字病理学工作流程，以缩短研究时间并提高运营效率。这种演变很重要，因为客户越来越寻求更快、更高效、数据更丰富的开发流程。([ir.criver.com](https://ir.criver.com/news-releases/news-release-details/charles-river-accelerates-digital-pathology-ai-powered-end-end?utm_source=openai)) 在地理上，Charles River 为全球主要生命科学市场的客户提供服务，在北美、欧洲和亚洲拥有重要的业务。公司近期发展突出了一项专注于创新、合作和先进模式的战略：它延长了与 CHDI Foundation 长期进行的亨廷顿病研究合作，扩大了细胞和基因疗法计划，并宣布其人工智能驱动的数字病理学平台持续发展势头。这些发展支持了公司的长期定位，尽管业绩仍受制药和生物技术研发支出周期的影响。([ir.criver.com](https://ir.criver.com/news-releases/news-release-details/charles-river-and-chdi-foundation-extend-multi-decade/?utm_source=openai))
